Dr. Kaddurah-Daouk trained in biochemistry at the American University of Beirut with post graduate training in molecular biology and genetics at Johns Hopkins where she worked with Nobel Laureate Hamilton Smith. She did subsequent training at the Massachusetts General Hospital followed by appointment in the Biology department at the Massachusetts Institute of Technology. Dr. Kaddurah-Daouk has been a seminal force in the development and evolution of the metabolomics field. She is an inventor on the earliest patents  that define comprehensive applications of metabolomics in the medical field. She cofounded the Metabolomics Society, served as its founding president and over a period of five years catalyzed organization of national and international meetings in US, Asia and Europe to promote research and create a community for metabolomics researchers. Membership grew to over 500 with participation from over twenty countries. She also founded a leading biotechnology company “Metabolon” devoted to metabolomics applications and hired its initial management team. Dr. Kaddurah-Daouk has extensive experience in assembling teams of researchers to work collaboratively on large scientific projects and has lead scientific programs from an early stage of discovery through clinical trials. She established and leads the Pharmacometabolomics Research Network with funding from NIGMS with the goal of integration of metabolomics and clinical pharmacology in an effort to personalize treatment. Additionally she has built a comprehensive metabolomics program at Duke for defining biochemical underpinnings of neuropsychiatric diseases and mapped early signatures for depression, schizophrenia and Alzheimer’s disease. During the earlier part of her career and over a period of ten years she focused on energy impairment in neurodegenerative disease. Her discoveries around the creatine kinase system resulted in identification of neuroprotective properties of creatine that lead to NIH funded phase II and III studies with creatine in over fifty clinical centers for the treatment of Parkinson’s and Huntington’s diseases. Dr. Kaddurah-Daouk is an inventor on over forty patents  and patent applications and has lead major projects  from basic discoveries to bedside. She has also started several not for profit organization for promoting scientific research and raised significant funds to enable their activities. She sits on the board of several organizations and is a member of the Clinical Neuroscience and Neurodegeneration Study Section at NIH.
Anastasia Georgiades, PhD 
E-mail: Anastasia.Georgiades@duke.edu 
Dr. Anastasia Georgiades research interest is focused on assessing risk factors in the development of hypertension, type 2 diabetes and cardiovascular disease. As a postdoctoral fellow both at Duke and the Karolinska Institute in Sweden, she coordinated and evaluated multi-site intervention studies on the effects of diet, exercise and stress management in hypertensive and cardiac patients. For the past 5 years she has been an Assistant Research Professor at Duke working on examining bio-behavioral mechanisms in the development of type 2 diabetes. Currently, she is a key member of the Duke team of the Pharmacometabolomics Network lead by Dr Kaddurah-Doauk and is involved in coordinating the antiplatelet therapy program. In addition to coordinating studies she is working on the development and implementation of standard operating procedures for the acquired clinical meta-data.